The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s antibody drug conjugates market report forecasts the antibody drug conjugates market size to grow to $16.15 Billion by 2027, with a CAGR (compound annual growth rate) of more than 22%.

Learn More On The Antibody Drug Conjugates Market Report 2023 – https://www.thebusinessresearchcompany.com/report/antibody-drug-conjugates-global-market-report

Antibody Drug Conjugates Market Size Forecast
The global antibody drug conjugates market is expected to grow from $5.9 billion in 2022 to $7.2 billion in 2023 at a compound annual growth rate (CAGR) of 22.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The antibody drug conjugates market is expected to grow from $16.15 billion in 2027 at a CAGR of 22.4%.

North America held the largest antibody drug conjugates market share, and Middle East was the fastest-growing region in 2022.

Key Antibody Drug Conjugates Market Driver ­– Rise In The Incidence Of Cancer Globally
The major causes of most cancers include obesity, smoking, alcohol, and improper eating habits. Cancer Research UK predicts that there will be 27.5 million new cases of cancer each year by 2040. The rising incidences of cancer are expected to increase the demand for antibody-drug conjugates, driving the market’s growth.

Request for A Sample Of The Global Antibody Drug Conjugates Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2569&type=smp

Key Antibody Drug Conjugates Market Trend – Partnering With Other Companies To Share Technology
Manufacturers of antibody-drug conjugates are increasingly collaborating or partnering with other companies to share technology, resources, and product knowledge and expand the business. For instance, in March 2022, Sanofi, a France-based multinational pharmaceutical and healthcare company, collaborated with a US-based biotechnology company, Seagen Inc., to create up to three cancer targets for antibody-drug conjugates (ADCs), develop them, and market them. The collaboration would make use of the exclusive monoclonal antibody (mAb) technology from Sanofi and the exclusive ADC technology from Seagen. Through this cooperation, candidate medications with the potential to give cancer patients and their families fresh hope would be created via the synergistic combination of molecules and platforms.

Antibody Drug Conjugates Market Segment

1) By Type: Monoclonal Antibodies, Linker, Drug/Toxin, Other Types

2) By Application: Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor, Other Applications

3) By Product: Adcertis, Kadcyla, Other Products

4) By Technology: Immunogen Technology, Seattle Genetics Technology, Immunomedics Technology, Other Technology

5) By End User: Hospital, Clinics, Other End Users

Antibody Drug Conjugates Market Major Players and Strategies
Major players in the antibody drug conjugates market are Bayer AG, Concortis Biotherapeutics, F. Hoffmann-La Roche Ltd., Immunomedics Inc., Oxford BioTherapeutics, Pfizer Inc., Seattle Genetics Inc., Takeda Pharmaceutical Company Limited, Abbvie Inc., and Astellas Pharma/Agensys.

The Antibody Drug Conjugates Global Market Report 2023 covers regional data on antibody drug conjugates market size, antibody drug conjugates market trends and drivers, opportunities, strategies, and antibody drug conjugates market competitor analysis. The countries covered in the antibody drug conjugates market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Antibody-drug conjugates (ADCs) refer to medications that are specifically designed to administer chemotherapy to cancer cells. ADCs deliver chemotherapy via a linker connected to a monoclonal antibody that binds to a specific target expressed on cancer cells.As soon as the ADC binds to its target (a cancer protein or receptor), a cytotoxic chemical is released into the cancer cell.

View More Reports Related To The Antibody Drug Conjugates Market –

Musculoskeletal Disorders Drugs Global Market Report 2022

Metabolic Disorders Drugs Global Market Report 2022

Antisense & RNAi Therapeutics Global Market Report 2022

Email us at [email protected]

Call us at:

Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708

Follow us on:

LinkedIn: https://bit.ly/3WzV8lZ

YouTube: https://bit.ly/3jiemhz

Global Market Model: https://bit.ly/3Was30B